The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL)

被引：0
|
作者：
Yilmaz, Musa [1 ]
Kantarjian, Hagop M. [2 ]
Ravandi, Farhad [2 ]
Jorgensen, Jeffrey L. [3 ]
Wang, Sa [3 ]
Garcia-Manero, Guillermo [2 ]
Cortes, Jorge E. [2 ]
Sasaki, Koji [2 ]
DiNardo, Courtney [2 ]
Kadia, Tapan [2 ]
Autry, Jane [2 ]
Garris, Rebecca [2 ]
Jabbour, Elias [2 ]
机构：
[1] Baylor Coll Med, Dept Hematol & Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] In vitro resistance to prednisolone is related to minimal residual disease (MRD) after induction therapy in childhood acute lymphoblastic leukemia (ALL)
    de Haas, V
    Kaspers, GJL
    Oosten, L
    Bresters, D
    Wijkhuijs, AJM
    van den Berg, H
    van der Schoot, CE
    LEUKEMIA, 2001, 15 (03) : 510 - 510
  • [42] In vitro resistance to predulsolone is related to minimal residual disease (MRD) after induction therapy in childhood acute lymphoblastic leukemia (ALL)
    de Haas, V
    Kaspers, GJL
    Oosten, L
    Bresters, D
    Wijkhuijs, AJM
    van Wering, ER
    van den Berg, H
    van der Schoot, CE
    LEUKEMIA, 2001, 15 (12) : 2014 - 2015
  • [43] Pursuing the Clonal Dynamics of Minimal Residual Disease (MRD) in Relapsed and Refractory Acute Myeloid Leukemia
    Kim, Dongchan
    Song, Hyojin
    Yoon, Sung-Soo
    Gwak, Daehyeon
    Yun, Hongseok
    Shin, Dong-Yeop
    BLOOD, 2022, 140 : 11819 - 11820
  • [44] Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant
    Zhang, Jianping
    Yang, Junfang
    Zhang, Xian
    Li, Jingjing
    Cao, Xingyu
    Zhao, Yanli
    Wei, Zhijie
    Liu, Deyan
    Xiong, Min
    Lu, Yue
    Zhou, Jiarui
    Sun, Ruijuan
    Lu, Peihua
    BLOOD, 2020, 136
  • [45] Inotuzumab Ozogamicin (IO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) as Frontline Therapy for Older Patients (pts) and as Salvage Therapy for Adult with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
    Jabbour, Elias
    O'Brien, Susan
    Thomas, Deborah
    Sasaki, Koji
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Borthakur, Gautam
    York, Sergermne
    Garris, Rebecca
    Cortes, Jorge
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S171 - S171
  • [46] The Prognostic Significance of Translocation (1;19) in Adult Patients (Pts) with B-Cell Acute Lymphoblastic Leukemia (ALL)
    Yilmaz, Musa
    Devendra, K. C.
    Akosile, Mary Abisola
    Khoury, Joseph David
    Short, Nicholas J.
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kadia, Tapan
    Sasaki, Koji
    Konopleva, Marina
    Wierda, William G.
    Jain, Nitin
    Verstovsek, Srdan
    Estrov, Zeev
    Pierce, Sherry
    O'Brien, Susan M.
    Jabbour, Elias J.
    Kantarjian, Hagop M.
    BLOOD, 2017, 130
  • [47] Heterogeneity of Minimal/Measurable Residual Disease (MRD) Practices in Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in the United States
    Hidalgo-Lopez, Juliana E.
    Roboz, Gail J.
    Wood, Brent
    Borowitz, Michael J.
    Jabbour, Elias J.
    Velasco, Kelly
    Elkhouly, Ehab
    Adedokun, Babatunde
    Zaman, Faraz
    Iskander, Karim
    Logan, Aaron
    BLOOD, 2021, 138
  • [48] Safety and activity of blinatumomab for older patients (pts) with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) in two phase 2 studies.
    Kantarjian, Hagop M.
    Stein, Anthony Selwyn
    Bargou, Ralf C.
    Grande, Carlos
    Larson, Richard A.
    Stelljes, Matthias
    Benjamin, Jonathan Eliot
    Jia, Catherine
    Topp, Max S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Factors influencing outcomes in patients (Pts) with relapsed/refractory b-precursor acute lymphoblastic leukemia (r/r ALL) treated with blinatumomab in a phase 2 study.
    Kantarjian, Hagop
    Goekbuget, Nicola
    O'Brien, Susan Mary
    Stein, Anthony Selwyn
    Jia, Catherine
    Forman, Stephen J.
    Bargou, Ralf C.
    Fielding, Adele K.
    Heffner, Leonard T.
    Larson, Richard A.
    Neumann, Svenja
    Maniar, Tapan
    Nagorsen, Dirk
    Topp, Max S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Queudeville, Manon
    Schlegel, Patrick
    Heinz, Amadeus T.
    Lenz, Teresa
    Doering, Michaela
    Holzer, Ursula
    Hartmann, Ulrike
    Kreyenberg, Hermann
    von Stackelberg, Arend
    Schrappe, Martin
    Zugmaier, Gerhard
    Feuchtinger, Tobias
    Lang, Peter
    Handgretinger, Rupert
    Ebinger, Martin
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 106 (04) : 473 - 483
12345